Clinical Trial Update: A Study to Evaluate the Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of TAK-079 in Combination With Standard Background Therapy in Participants With Moderate to Severe Systemic Lupus Erythematosus (SLE) [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating TAK-079 in combination with standard therapy in moderate to severe systemic lupus erythematosus; study completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• TAK-079

Snippet

Sponsor: Millennium Pharmaceuticals, Inc. | Conditions: Systemic Lupus Erythematosus, Lupus Erythematosus, Systemic | Phase 1 | Status: COMPLETED | Results posted: 2024-03-29